TrialJapanese journal of clinical oncology2026
A multicenter randomized phase II/III trial of salvage treatment for refractory primary central nervous system lymphoma using tirabrutinib: JCOG2314 (ReSTART).
Kota Kawabata et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.